Kiniksa Pharmaceuticals Market Sentiment

Kiniksa Pharmaceuticals International PLC

KNSANASDAQ

Trade with Public

$78.53

-0.71-0.9%

Ult. Agg.: Oct 13, 4:00 PM

$79.30

0.060.08%

Panoramica Notizie Previsioni utili Eventi Obiettivi di prezzo Dati finanziariSentimentAzionariato Confronta Opzioni Rapporto azionario

Kiniksa Pharmaceuticals Market Sentiment

Market sentiment signals for Kiniksa Pharmaceuticals (KNSA): analyst consensus, short interest, options flow and insider activity.

Key Signals

Analyst Consensus▲ Buy

Short Interest▲ 9.4% short float

Options Flow▲ 0.07 P/C ratio

Insider Activity— N/A

Analyst Consensus

Buy

9 analysts

Options Flow (P/C)

0.07

More calls — Bullish

553 calls · 40 puts

Avg Consensus PT

$82

+3.9%

Highest Price Target

$107

+36.3%

JP Morgan

Lowest Price Target

$35

-55.4%

Evercore ISI Group

Short Interest

9.4%

Declining — Bullish

Insider Activity (30d)

—

Short Interest — % of Float

Recent Analyst Actions

Date	Firm	Analyst & Accuracy	Upside / Downside	PT Change	Action	Rating
Jul 30, 2026	Goldman Sachs	Paul Choi—	+14.6%	$75 → $90	Maintained	Buy
Jul 29, 2026	JP Morgan	Anupam Rama—	+36.3%	$72 → $107	Maintained	Overweight
Jul 29, 2026	Canaccord Genuity	Edward Nash—	+24.8%	$64 → $98	Maintained	Buy
Jul 29, 2026	Wedbush	David Nierengarten—	+26.1%	$72 → $99	Maintained	Outperform
Jul 29, 2026	Citigroup	Geoff Meacham—	+27.3%	$60 → $100	Maintained	Buy
Jul 23, 2026	Goldman Sachs	Paul Choi—	-4.5%	$60 → $75	Maintained	Buy
Jul 13, 2026	Wells Fargo	Eva Fortea Verdejo—	-5.8%	$57 → $74	Maintained	Overweight
Jun 29, 2026	Wedbush	David Nierengarten—	-8.3%	$59 → $72	Maintained	Outperform
Apr 29, 2026	Canaccord Genuity	Edward Nash—	-18.5%	$62 → $64	Maintained	Buy
Apr 29, 2026	Citigroup	Geoff Meacham—	-23.6%	$50 → $60	Maintained	Buy
Apr 29, 2026	Wedbush	David Nierengarten—	-24.9%	$58 → $59	Maintained	Outperform
Apr 29, 2026	Wells Fargo	Eva Fortea Verdejo—	-27.4%	$53 → $57	Maintained	Overweight
Apr 28, 2026	Jefferies	Roger Song—	-9.6%	$58 → $71	Maintained	Buy
Apr 16, 2026	Wedbush	David Nierengarten—	-26.1%	$53 → $58	Maintained	Outperform
Feb 25, 2026	Wells Fargo	Eva Fortea Verdejo—	-32.5%	$50 → $53	Maintained	Overweight
Feb 25, 2026	Wedbush	David Nierengarten—	-32.5%	$50 → $53	Maintained	Outperform
Feb 19, 2026	Canaccord Genuity	Edward Nash—	-21.0%	$62	Initiate	Buy
Jan 13, 2026	Wedbush	David Nierengarten—	-36.3%	$48 → $50	Maintained	Outperform
Oct 29, 2025	Goldman Sachs	Paul Choi—	-30.0%	$45 → $55	Maintained	Buy
Oct 17, 2025	Citigroup	Geoff Meacham—	-36.3%	$45 → $50	Maintained	Buy
Oct 13, 2025	Wedbush	David Nierengarten—	-44.0%	$38 → $44	Maintained	Outperform
Sep 29, 2025	TD Cowen	Nicholas Lorusso—	-23.6%	$60	Initiate	Buy
Sep 25, 2025	Wells Fargo	Eva Fortea Verdejo—	-42.7%	$42 → $45	Maintained	Overweight
Jul 29, 2025	Jefferies	Roger Song—	-31.2%	$45 → $54	Maintained	Buy
Jul 9, 2025	Wells Fargo	Eva Fortea Verdejo—	-46.5%	$30 → $42	Maintained	Overweight